Graticule Appoints Patrick Wulf Hanson as Chief Alliance Officer for EU Operations
5.9.2023 17:00:00 EEST | Business Wire | Press release
Graticule, a Real World Data CRO that conducts life science research and development projects with both USA and International data partners, is pleased to announce the onboarding of Patrick Hanson as the Chief Alliance Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831939371/en/
Patrick Wulf Hanson (Photo: Business Wire)
Daniel Poscover, Founder and CEO of Graticule, mentioned, “We are thrilled to welcome Patrick to our leadership team. With his vast experience in stakeholder management, engagement, and close interactions with Key Opinion Leaders (KOLs) and regulatory authorities, I am confident that we can broaden our EU operations to a much larger network.”
Patrick has over 30 years of experience in the pharmaceutical industry, consultancy, and academia. He previously served as Vice President for Real-World Data Alliances Europe at Lumanity, Head of Real World Data Strategy Europe and Canada at Parexel, Director of Real-World Analytics & Solutions Nordics (and Head of Denmark) at IQVIA, Nordic medical director at McCann Health Nordic, Scientific Director at Cohn & Wolfe and Molecule Consultancy, and Director of Global Product Safety, Regulatory Affairs Officer, and Corporate Branding at Novo Nordisk. Before his industry work, Patrick held research and teaching positions in Sweden, Denmark, and the USA. He has also authored textbooks and peer-reviewed articles.
Patrick's vast network and diverse European experience will help introduce innovative business strategies and foster collaborations for Graticule's European operations. Patrick believes that his ability to create sustainable relationships and alliances, stakeholder engagement, communicate advanced medical content to any audience, and create value for customers and patients will help Graticule in becoming a leading player in the European market.
To learn more, visit Graticule.
About Graticule
Graticule is a Real World Data CRO that conducts life science research and development projects with both USA and International data partners. The company focuses on establishing relationships, tools, and expertise to overcome traditional barriers that have limited the applications of medical data. Graticule solutions include comparative effectiveness studies, surveillance, patient identification, clinical trial recruitment, and an automated data transfer to Electronic Data Capture systems. The company differentiates itself by focusing on timely access to relevant patient data through close engagement with both Graticule Research Network and project-specific data partners. The result of the approach is a team that can rapidly leverage advanced data sets such as clinical notes, imaging, genetic testing, and structured clinical data and can scale research to large populations over time. Our solutions include Graticule Study Source, Graticule Patient Finder, and Graticule CLEHR.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831939371/en/
Contact information
Kyle F. Conley
Vice President of People Operations, Privacy Official
kconley@graticule.life
(617) 412-0999
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom